The Triple Test, also called the triple screen test, triple marker screening test, or triple screen blood test, is a second-trimester prenatal screening test. It uses a pregnant woman’s blood sample to estimate the risk of certain fetal conditions, including Down syndrome, Edwards syndrome, and open neural tube defects.
The test is non-invasive and does not diagnose a condition by itself. Instead, it helps doctors decide whether further evaluation, ultrasound review, cell-free DNA screening, genetic counseling, or diagnostic testing such as amniocentesis may be needed.
This guide explains what the triple test is, when it is done, what the results may indicate, the cost of the triple screen test in India, and what patients should discuss with their doctor after receiving results.
What Is the Triple Test?
The triple test is a maternal blood screening test usually performed during the second trimester of pregnancy. It measures three substances in the mother’s blood:
| Marker | What It Is |
|---|---|
| Alpha-fetoprotein (AFP) | A protein produced mainly by the fetal liver |
| Human chorionic gonadotropin (hCG) | A hormone produced by the placenta |
| Unconjugated estriol (uE3) | An estrogen produced by the fetus and placenta |
These values are combined with factors such as maternal age, gestational age, weight, diabetes status, smoking status, and pregnancy details to estimate risk.
The triple marker screening test may help assess the risk of:
- Trisomy 21, also called Down syndrome
- Trisomy 18, also called Edwards syndrome
- Open neural tube defects such as spina bifida or anencephaly
The triple test is not diagnostic. A high-risk result only means that further evaluation may be recommended.
Triple Screen Test in Pregnancy: When Is It Done?
The triple screen test in pregnancy is usually done between 15 and 20 weeks of gestation, with many clinicians preferring the 16–18 week window for accurate interpretation.
Some screening programs or laboratories may allow second-trimester serum screening up to 22 weeks, depending on the protocol used. The exact testing window should be confirmed with the doctor or the testing laboratory.
Correct gestational age is very important. If the pregnancy dating is incorrect, the triple test result may show a false high-risk or low-risk estimate.
Interpreting Triple Test Results
The results of the triple screen blood test are interpreted by factoring in multiple variables:
- Maternal age
- Gestational age
- Weight
- Ethnicity
- Presence of insulin-dependent diabetes
- Smoking status
Based on these factors and the measured levels of AFP, hCG, and uE3, a statistical model is used to estimate the risk of specific fetal conditions.
High or Low Levels: What They Indicate
High AFP: May indicate neural tube defects, abdominal wall defects, or underestimated gestational age.
Low AFP and estriol, high hCG: May suggest an increased risk of Down syndrome.
Low levels of all three markers: May indicate an increased risk of Trisomy 18.
It’s crucial to remember that an abnormal result doesn’t confirm a diagnosis; it only indicates increased or decreased risk.
Triple Test Normal Values and MoM
Triple test results are usually interpreted using MoM, which means “multiples of the median.” MoM compares the patient’s marker level with the expected median value for that gestational age.
A value around 1.0 MoM is generally close to the expected median, but the acceptable range may vary by lab, population, method, and pregnancy factors.
| Marker | General Interpretation |
|---|---|
| AFP | High or low AFP may affect risk assessment for neural tube defects or chromosomal conditions |
| hCG | Higher or lower hCG may contribute to trisomy risk calculations |
| uE3 | Low uE3 may be considered in chromosomal risk assessment |
Many labs consider marker values roughly between 0.5 and 2.5 MoM as within an expected range, but this should not be used for self-interpretation. Always follow the risk interpretation and reference ranges provided in the laboratory report.
What Happens After an Abnormal Triple Test Result?
An abnormal triple screen test result does not confirm that the baby has a genetic or structural condition. It only means the estimated risk is higher than the screening cut-off used by the laboratory.
Follow-up may include:
| Follow-Up Step | Purpose |
|---|---|
| Detailed ultrasound | To confirm gestational age, check fetal anatomy, and look for visible anomalies |
| Genetic counseling | To explain the result, risk estimate, and next testing options |
| Cell-free DNA testing | A more accurate non-invasive screening option for common chromosomal conditions |
| Amniocentesis | A diagnostic test that can confirm chromosomal abnormalities |
| Repeat or additional testing | May be advised if dates, sample quality, or clinical details need review |
Cell-free DNA testing can provide stronger risk assessment, but it is still considered a screening test. Diagnostic confirmation usually requires procedures such as amniocentesis or chorionic villus sampling, depending on gestational age and clinical advice.
Triple Screen Test Cost in India
The triple screen test cost in India usually varies by city, laboratory, hospital, and whether the test is included in a prenatal screening package. In many locations, the cost may range from around ₹1,500 to ₹3,500.
The final cost may depend on:
- City and lab brand
- Hospital vs standalone diagnostic lab
- Sample collection charges
- Doctor consultation or counseling charges
- Whether ultrasound or other tests are included
- Whether the patient chooses triple test, quadruple test, or cell-free DNA screening
Patients should confirm the exact price, test window, report timeline, and follow-up requirements with their doctor or diagnostic centre before booking.
Advantages and Limitations
Advantages
- Non-invasive and safe for both mother and fetus
- Can be performed in routine outpatient settings
- Helps stratify patients for further testing
Limitations
- Not diagnostic; false positives and false negatives can occur
- Accuracy depends heavily on gestational age and maternal factors
- Does not detect all genetic or structural conditions
Triple Test vs Other Prenatal Screening Options
| Test | Usual Timing | What It Checks | Diagnostic? | Key Point |
|---|---|---|---|---|
| Triple Test | Usually 15–20 weeks | AFP, hCG, uE3 | No | Affordable second-trimester screening option |
| Quadruple Test | Second trimester | AFP, hCG, uE3, inhibin A | No | Adds inhibin A and may improve screening performance |
| First-Trimester Screening | 11–13 weeks | Blood markers + nuchal translucency ultrasound | No | Earlier screening option |
| Cell-Free DNA / NIPT | From around 10 weeks | Common fetal chromosomal conditions | No | More sensitive screening, but not diagnostic |
| Amniocentesis | Usually after 15 weeks | Fetal chromosomes/genetic diagnosis | Yes | Diagnostic test, but invasive |
Choosing the appropriate test depends on gestational age, patient risk factors, cost, and resource availability.
Mayo Clinic Laboratories describes the quad screen as a four-marker screen using AFP, estriol, hCG, and inhibin A, and ACOG notes cfDNA is a screening test that should be offered with counseling rather than treated as diagnosis.
For Diagnostic Labs: Why Accurate Prenatal Screening Reports Matter
Prenatal screening reports require accurate patient details, gestational age, sample information, biomarker values, MoM calculation, risk interpretation, and clear report delivery.
For diagnostic laboratories, a structured reporting workflow helps reduce manual errors and ensures reports are reviewed and delivered consistently.
FLABS LIS helps pathology labs manage patient registration, sample tracking, report templates, approval workflows, and digital report delivery from one connected platform.
Explore FLABS LIS Software
Learn About Pathology Reporting Software
Conclusion
The triple test in pregnancy remains a valuable screening tool, particularly in settings where more advanced options may not be feasible. For healthcare providers and pathologists, understanding the timing, interpretation, and follow-up of the triple screen test is key to guiding expectant mothers through informed, evidence-based prenatal care.
With proper application, the triple marker screening test continues to support early detection and risk assessment, enhancing the quality and precision of prenatal care across diverse clinical settings.
Medical Disclaimer: This article is for educational purposes only and should not be used as medical advice or a diagnosis. The triple test is a screening test, not a diagnostic test. Results should be interpreted by a qualified doctor, obstetrician, genetic counselor, or healthcare professional based on gestational age, ultrasound findings, maternal history, and other clinical factors.
Get Started at ₹1!
Try Flabs for a full month for just ₹1.
Follow us on
